文献速递流行病学与生物统计临床试验与 GCP新药、器械与细胞基因治疗研发

2026-2027呼吸道季节RSV免疫接种有效性与安全性

RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season.
PubMed 文献 · JAMA · 2026-09-02

该证据综述检索截至2026年6月29日的文献,纳入75项研究(含12项随机临床试验),评估美国获批RSV疫苗和单克隆抗体的有效性及安全性。结果显示,老年人接种疫苗对RSV相关住院的疫苗有效性为83.3%(95%CI 42.9%-96.9%);孕期接种对婴儿RSV相关住院的有效性为51.0%-70.0%;尼塞韦单抗对婴儿RSV相关住院的有效性为63.6%-93.0%。特殊关注不良事件与既往综述一致。

要点

  • 老年人RSV疫苗接种对RSV相关住院的VE为83.3%(95%CI 42.9%-96.9%)。
  • 孕期32-36周接种对婴儿RSV相关住院的VE为51.0%-70.0%。
  • 婴儿使用尼塞韦单抗对RSV相关住院的VE为63.6%-93.0%。

核心结论

  • RSV免疫接种与严重RSV和RSV相关住院风险降低相关。
  • 老年人证据提示后续季节RSV疫苗有效性可能降低。
  • 特殊关注不良事件(包括吉兰-巴雷综合征和早产)与既往综述一致。

研究设计与样本

  • 证据综述检索MEDLINE、Embase、Cochrane CENTRAL和Scopus,时间范围2025年8月1日至2026年6月29日。
  • 共纳入75项符合条件的研究:12项随机临床试验、33项有对照组的观察性研究、16项无对照组的观察性研究和14项RSV流行病学描述性研究。
  • 数据提取覆盖老年人(≥60岁)、成人、免疫受损者、婴儿、儿童及孕期接种者,并使用Cochrane工具评估偏倚风险。

主要发现

  • 老年人RSV疫苗接种对RSV相关住院的VE为83.3%(95%CI 42.9%-96.9%)。
  • 一项研究中,老年人接种后第一季对住院和实验室确诊RSV疾病的VE点估计显著高于随访12-18个月时。
  • 孕期接种(32-36周)对婴儿RSV相关住院的VE范围为51.0%(95%CI -29.6%-83.3%)至70.0%(95%CI 37.0%-86.0%)。
  • 婴儿尼塞韦单抗对RSV相关住院6-12个月内的有效性估计随时机而异,范围为63.6%(95%CI 26.9%-81.9%)至93.0%(95%CI 83.0%-97.0%)。
  • 3项随机临床试验中未发现吉兰-巴雷综合征病例;一项自控病例系列报告老年人接种后42天内吉兰-巴雷综合征风险可能增加。

关键数值与推荐

  • 老年人RSV疫苗对RSV相关住院的VE为83.3%(95%CI 42.9%-96.9%)。
  • 孕期接种对婴儿RSV相关住院的VE为51.0%(95%CI -29.6%-83.3%)至70.0%(95%CI 37.0%-86.0%)。
  • 婴儿尼塞韦单抗对RSV相关住院6-12个月内的有效性为63.6%(95%CI 26.9%-81.9%)至93.0%(95%CI 83.0%-97.0%)。

临床怎么用

  • 老年人接种RSV疫苗可降低RSV相关住院风险,但后续季节有效性可能降低。
  • 孕期32-36周接种可降低婴儿RSV相关住院风险。
  • 婴儿使用尼塞韦单抗可降低RSV相关住院风险,有效性随接种时机变化。

局限性

  • 一项自控病例系列提示老年人接种后42天内吉兰-巴雷综合征风险可能增加,需进一步监测。
  • 一项研究中第一季与随访12-18个月的VE差异在另一项比较1季与2季的研究中不显著。
  • 本综述纳入的比较性研究均未发现孕期接种与早产或其他不良妊娠结局的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory tract infection and a contributor to morbidity and mortality. OBJECTIVE: To synthesize evidence from recent randomized clinical trials and observational studies reporting on the effectiveness and safety of RSV vaccines and monoclonal antibodies and the epidemiology of RSV in the US. EVIDENCE REVIEW: Databases including MEDLINE (PubMed), Embase, Cochrane CENTRAL, and Scopus were searched from August 1, 2025, through June 29, 2026, for studies evaluating the safety and effectiveness of US-licensed RSV vaccines or RSV monoclonal antibody products or describing RSV epidemiology. Data were extracted for older adults (≥60 years), adults, immunocompromised persons, infants, children, and individuals vaccinated during pregnancy. Reviewers assessed risk of bias (RoB) using Cochrane tools for randomized and observational studies. FINDINGS: A total of 75 eligible studies were identified, including 12 randomized clinical trials (RCTs), 33 observational studies with a comparator group, 16 observational studies without a comparator group, and 14 descriptive studies on RSV epidemiology. Among older adults, RSV vaccination was associated with a reduction in RSV-related hospitalization (vaccine effectiveness [VE], 83.3%; 95% CI, 42.9% to 96.9%). Point estimates for RSV VE against hospitalization and laboratory-confirmed RSV illness among older adults were significantly higher during the first season after vaccination compared with 12 to 18 months of follow-up in 1 study, although the difference was not significant when comparing VE after 1 season vs 2 seasons in another study. The VE for maternal vaccination (between 32-36 weeks' gestation) ranged from 51.0% (95% CI, -29.6% to 83.3%) to 70.0% (95% CI, 37.0% to 86.0%) against RSV-related infant hospitalization. Estimates for effectiveness of nirsevimab among infants varied by timing ranged from 63.6% (95% CI, 26.9% to 81.9%) to 93.0% (95% CI, 83.0% to 97.0%) for RSV-related hospitalization within 6 to 12 months. No cases of Guillain-Barré syndrome (GBS) were identified across 3 RCTs; among older adults, 1 self-controlled case series reported a possible increased risk of GBS during the 42 days following vaccination. None of the comparative studies included in this review found an association of RSV vaccination during pregnancy with preterm birth or other adverse pregnancy outcomes. CONCLUSIONS AND RELEVANCE: RSV immunizations were associated with reduced risk of severe RSV and RSV-related hospitalizations; evidence among older adults suggests that RSV VE may be lower in subsequent seasons. Reported adverse events of special interest (including GBS and preterm birth) were consistent with prior reviews. The results of this updated review are both consistent with previously reported evidence and provide new insight into several aspects of RSV immunizations.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Senerth E, Sheikholeslamian SM, Babatunde I, et al. RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season. JAMA. 2026. PMID: 42684247. doi:10.1001/jama.2026.17871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。